About Pasithea Therapeutics Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.pasithea.com/
Frequently Asked Questions
What is the 52-week range for KTTA?
The 52-week high is $2.06 and the 52-week low is $0.281.
What is the P/E ratio for KTTA?
The P/E ratio data is currently unavailable.
What is the dividend yield for KTTA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -49.49%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -6478.41%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.27.
Analyst Recommendation Trends
Wall Street analyst consensus for KTTA over the last few months:
Latest KTTA News
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million. Geovax Labs (NASDAQ:GOVX) stock rose
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - The European Neurofibromatosis Conference 2026 will take place in Vienna, Austria, from November 12–14, 2026 MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004,
Pasithea Sets November Debut For Early PAS-004 Clinical Trial Results
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-17 | Coastlands Capital LP | +100,000 | $0.53 | $53,000 |
| 2026-05-01 | Marques Tiago | +1,756,069 | - | - |
| 2026-05-01 | Dumesnil Simon | +152,783 | - | - |
| 2026-05-01 | Krishnan Kartik | +1,129,323 | - | - |
| 2026-05-01 | Leahy Emer | +152,783 | - | - |
| 2026-05-01 | Schneiderman Daniel H | +1,129,323 | - | - |
| 2026-05-01 | Novak Alfred J | +152,783 | - | - |
| 2026-05-01 | STEINMAN LAWRENCE | +152,783 | - | - |
| 2025-11-28 | Marques Tiago | +33,333 | $0.75 | $25,000 |
| 2025-11-28 | Dumesnil Simon | +33,333 | $0.75 | $25,000 |
| 2025-11-28 | Leahy Emer | +33,333 | $0.75 | $25,000 |
| 2025-11-28 | Schneiderman Daniel H | +26,667 | $0.75 | $20,000 |
| 2025-11-28 | STEINMAN LAWRENCE | +133,333 | $0.75 | $100,000 |
| 2025-10-24 | Novak Alfred J | +42,913 | - | - |
| 2025-10-24 | Marques Tiago | +493,341 | - | - |
| 2025-10-24 | Leahy Emer | +42,913 | - | - |
| 2025-10-24 | Dumesnil Simon | +42,913 | - | - |
| 2025-10-24 | Schneiderman Daniel H | +317,266 | - | - |
| 2025-10-24 | STEINMAN LAWRENCE | +242,913 | - | - |